The company pays special attention to research and development, and set up a research and development center at the beginning of the company. At present, the number of professional and technical personnel engaged in technology research and development accounts for nearly 20% of the total number of the company, of which more than 60% of the technical personnel with bachelor's degree, more than 30% of the technical personnel with graduate degree, and more than 3% of the annual R & D expenses and sales revenue.

The company's R & D center has a reasonable layout, covering an area of more than 1500 square meters, and is equipped with complete small-scale synthesis, pilot-scale amplification, production trial production, product testing and other equipment to support the promotion and industrialization of new products and technologies. The scientific research equipment of the R & D center is at a high level in China. It has a fixed bed reactor, infrared spectrometer, high performance liquid chromatography, gas chromatography and other advanced synthesis and detection equipment, which is a strong support for drug research and development.

Vigorously carry out the construction of industry-university-research innovation mechanism, and successively signed school-enterprise cooperation agreements with Huanghuai College and Henan Vocational College of Applied Technology to jointly build a collaborative innovation platform for the new pharmaceutical industry in Zhumadian, provide public services in professional fields, and promote pharmaceutical testing and pharmaceutical research and development Technology, jointly cultivate talents, and promote the development of the industry and the transformation of results.

The company has strong technical force, and has successively established scientific research platforms such as Henan Province Antimicrobial Chemical Synthesis and Green Preparation Engineering Technology Research Center, Zhumadian City-level Enterprise Technology Center, and Zhumadian City Engineering Technology Research Center. The company always adheres to the concept of independent innovation and technology first, and promotes the construction of intellectual property field. By the end of 2024, it has obtained 2 authorized invention patents and 17 utility model patents.
The company's R & D center actively carries out technical cooperation and exchanges with powerful drug R & D institutions and manufacturers at home and abroad, and has successively developed cephalosporins represented by cefuroxime and hypoglycemic raw materials represented by daglitazone And preparations enable the company to maintain its advantages and leading position in industrial structure and production technology.